However, recent data from our laboratory [48] showed that specific inhibition of ErbB2 receptor with AG825 or siRNA had similar vascular effects as a dual EGFR/ErbB2 inhibitor implying that ErbB2 rather than EGFR may be the predominant signaling pathway involved in diabetes-induced vascular dysfunction. The gene discussed is ERBB2; the disease is diabetes mellitus.